CD274 and glioblastoma: An ongoing phase II trial is evaluating the anti-PD-L1 antibody durvalumab with radiotherapy and bevacizumab in GBM (NCT02336165), with preliminary results of the recurrent, bevacizumab-refractory cohort showing only 36% survival at 5.5 months [51].